These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16706956)

  • 1. Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review.
    Szucs TD; Bramkamp M
    J Thromb Haemost; 2006 Jun; 4(6):1180-5. PubMed ID: 16706956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
    Ruiz Vargas E; Sposato LA; Lee SAW; Hachinski V; Cipriano LE
    Stroke; 2018 Dec; 49(12):2844-2850. PubMed ID: 30571418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US.
    Sullivan PW; Arant TW; Ellis SL; Ulrich H
    Pharmacoeconomics; 2006; 24(10):1021-33. PubMed ID: 17002484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial.
    Cowper PA; Sheng S; Lopes RD; Anstrom KJ; Stafford JA; Davidson-Ray L; Al-Khatib SM; Ansell J; Dorian P; Husted S; McMurray JJV; Steg PG; Alexander JH; Wallentin L; Granger CB; Mark DB
    JAMA Cardiol; 2017 May; 2(5):525-534. PubMed ID: 28355434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective.
    Casciano JP; Dotiwala ZJ; Martin BC; Kwong WJ
    J Manag Care Pharm; 2013 May; 19(4):302-16. PubMed ID: 23627576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis.
    Desbiens NA
    J Am Geriatr Soc; 2002 May; 50(5):863-9. PubMed ID: 12028173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control.
    Janzic A; Kos M
    Pharmacoeconomics; 2015 Apr; 33(4):395-408. PubMed ID: 25512096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients.
    Nguyen E; Egri F; Mearns ES; White CM; Coleman CI
    Pharmacotherapy; 2016 May; 36(5):488-95. PubMed ID: 27015873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
    Wu B; Kun L; Liu X; He B
    Cardiovasc Drugs Ther; 2014 Feb; 28(1):87-98. PubMed ID: 24048510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What Influences the Cost Effectiveness of Dabigatran versus Warfarin for Stroke Prevention in Atrial Fibrillation: A Systematic Review.
    Jegathisawaran J; Holbrook A; Bowen JM; Burke N; Campbell K; Tarride JE
    J Popul Ther Clin Pharmacol; 2017 May; 24(2):e1-e20. PubMed ID: 28594478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5-Year, Long-Term Data.
    Reddy VY; Akehurst RL; Gavaghan MB; Amorosi SL; Holmes DR
    J Am Heart Assoc; 2019 Jul; 8(13):e011577. PubMed ID: 31230500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.
    Lanitis T; Kongnakorn T; Jacobson L; De Geer A
    Thromb Res; 2014 Aug; 134(2):278-87. PubMed ID: 24935675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
    Kamel H; Johnston SC; Easton JD; Kim AS
    Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
    O'Brien CL; Gage BF
    JAMA; 2005 Feb; 293(6):699-706. PubMed ID: 15701911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation.
    Amorosi SL; Armstrong S; Da Deppo L; Garfield S; Stein K
    Europace; 2014 Aug; 16(8):1131-6. PubMed ID: 24687964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia.
    Ademi Z; Pasupathi K; Liew D
    Eur J Prev Cardiol; 2015 Mar; 22(3):344-53. PubMed ID: 24281250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.
    Kleintjens J; Li X; Simoens S; Thijs V; Goethals M; Rietzschel ER; Asukai Y; Saka Ö; Evers T; Faes P; Vansieleghem S; De Ruyck M
    Pharmacoeconomics; 2013 Oct; 31(10):909-18. PubMed ID: 24030788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US.
    von Schéele B; Fernandez M; Hogue SL; Kwong WJ
    Ann Pharmacother; 2013 May; 47(5):671-85. PubMed ID: 23606551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation.
    Dorian P; Kongnakorn T; Phatak H; Rublee DA; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Lip GY
    Eur Heart J; 2014 Jul; 35(28):1897-906. PubMed ID: 24513791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.